Myriam Heiman takes over from Li Huei Tsai on July 1 with a research focus on why specific neurons die in Huntington's and Parkinson's, a different scientific bet than the institute's prior emphasis on memory and Alzheimer's.
When Li-Huei Tsai stepped down after 16 years leading MIT's Picower Institute for Learning and Memory, the institute's next director brought a different scientific bet. According to MIT News on June 10, Myriam Heiman, a neurobiologist who studies why specific neurons die in Huntington's and Parkinson's disease, will take the role effective July 1.
The transition marks a redirection for an institute whose identity under Tsai was bound to memory circuits and Alzheimer's. Heiman has spent her career on a narrower, harder question: which cell types in the basal ganglia are most vulnerable in Huntington's and Parkinson's, and why those cells fail where others survive.
That question has resisted clean answers. Decades of single-cell genomics and molecular profiling, including techniques Heiman helped develop, have mapped the cellular landscape of these diseases in extraordinary detail. They have not yet produced therapies that slow the underlying neurodegeneration. The MIT News announcement frames Heiman's work within a field whose clinical record on these diseases remains stubbornly mixed, a gap the institute's new leadership will inherit along with the directorship.
Heiman co-invented translating ribosome affinity purification (TRAP), a method that lets researchers profile gene expression in specific cell types by capturing the messenger RNA those cells are actively translating. Combined with single-cell genomics, TRAP has become a standard tool for asking which neurons are doing what in a healthy brain and which are failing in a diseased one. The technique's widespread adoption is one measure of Heiman's influence; the absence of curative therapies built on that knowledge is a measure of how much work remains.
Picower is a research institute within MIT's School of Science, small enough that the directorship sets the scientific tone for hiring, collaboration, and resource allocation. A leadership change at a privately funded institute of this size carries more weight than a similar announcement at a larger department.
The question the transition leaves open is whether Picower will maintain Tsai's broad portfolio on memory and cognitive decline or whether Heiman's appointment signals a tightening of focus toward the molecular biology of vulnerable cell populations. Both readings are defensible. The answer will depend on which faculty the institute recruits and which grants it prioritizes in the next funding cycle.
What is already clear is that the institute's incoming director has spent her career on a problem the field has not solved. The bet is not that the tools have failed, but that the right cell type, identified with enough precision, may yet point to a target that the past decade's therapies have missed.